GRACELL BIOTECHNOLOGIES-ADR (GRCL) Stock Income Statement
USA - NASDAQ:GRCL - US38406L1035 - ADR
10.25 USD
+0.01 (+0.05%)
10.25 USD
0 (0%)
| TTM (2023-6-30) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 370.00K | 0.00 | 0.00 | |||
| Operating Expenses | 626.84M | 624.66M | 463.94M | 214.40M | 146.58M | |||
| Research and Development | 487.80M | 485.39M | 326.90M | 168.83M | 119.22M | |||
| Selling, General, and Administrative Expenses | 139.05M | 139.27M | 137.04M | 45.57M | 27.36M | |||
| Operating Income | -626.84M | -624.66M | -463.57M | -214.40M | -146.58M | |||
| Interest Income/Expense | 17.09M | 9.01M | 2.76M | -2.20M | 6.49M | |||
| Other Income/Expense | 8.53M | 8.16M | 9.06M | 4.70M | 1.43M | |||
| Income Before Taxes | -601.23M | -607.49M | -451.75M | -211.90M | -138.66M | |||
| Income Tax | N/A | 20.00K | N/A | N/A | N/A | |||
| Net Income | -601.28M | -607.51M | -453.74M | -274.63M | -200.86M | |||
| EBITDA | N/A | -565.89M | -418.70M | -192.81M | -141.46M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -6.29 | -6.36 | -4.88 | -2.97 | -2.16 | |||
| Non GAAP EPS | -1.30 | -1.30 | -1.05 | N/A | N/A | |||
| Statistics | ||||||||
| Profit Margin | N/A | N/A | -122632.43% | N/A | N/A | |||
| Operating Profit Margin | N/A | N/A | -125289.19% | N/A | N/A | |||
All data in CNY